Hubbry Logo
Standard BioToolsStandard BioToolsMain
Open search
Standard BioTools
Community hub
Standard BioTools
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Standard BioTools
Standard BioTools
Standard BioTools
View on Wikipedia
from Wikipedia
Standard BioTools Canada

Key Information

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs),[3] and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

Standard BioTools sells products to academic research institutions; translational research and medical centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology and plant and animal research companies; and contract research organizations.

Business model

[edit]

Standard BioTools is a public company traded on the Nasdaq stock exchange, previously under the ticker symbol FLDM,[4] currently under LAB.

Its genomic analysis products create microfluidic devices or IFCs.[5][6] Genomics applications using IFCs processed on the Biomark™ X9 System for High-Throughput Genomics include gene expression and genotyping by PCR and NGS library preparation for pathogen detection, agrigenomics, sample identification and pharmacogenomics.

Its proteomic analysis products are based on technology developed by DVS Sciences, acquired by Fluidigm® in 2014.[6] DVS is best known for its multiparameter single-cell protein analysis systems,[7] which analyze antibody/metal complexes using atomic mass spectrometry. The technology enables precise, high-parameter single-cell protein analysis for applications in life sciences research.

The company has remained a pioneer in integrated microfluidic technology, with continued iterations of IFCs for a growing variety of applications.[citation needed] It is also the only company developing mass cytometry technologies for both flow cytometry and imaging applications.[citation needed]

History

[edit]

The company was founded in 1999 as Mycometrix by Stephen Quake and Gajus Worthington.[8] The company was formed to commercialize technology developed by Quake at the California Institute of Technology referred to as microfluidic large-scale integration and branded IFCs[1]. Richard DeLateur, a 20-year veteran of Intel, came on as chief financial officer in 2006.[9] Worthington was the company’s chief executive officer from its inception in 1999 to 2016. Quake has remained a member of the company’s scientific advisory board.

The company’s founders created integrated circuits that carried fluids rather than electrons. In 2009, the company was described as “the world’s leading manufacturer of microfluidic devices[5].” The company’s original microfluidics products were aimed for use in applications such as protein crystallization, genotyping, DNA analysis and PCR.

The company completed a successful initial public offering (IPO) in February 2011, raising about $75 million.[4] This followed a failed, ill-timed IPO in 2008.[10] As of the 2011 IPO, Fluidigm had not yet become profitable. Following a $250 million investment from Casdin Capital, LLC and Viking Global Investors LP in April 2022, Fluidigm changed its name to Standard BioTools.[11] This change in name emphasized their mission to create a diversified, scalable innovation-focused life science tools company serving the pharma research markets.[12]

The company acquired Nasdaq-listed SomaLogic in January 2024 in an all-stock deal.[13]

Operations

[edit]

At the end of 2023, Standard BioTools had a headcount of 500 personnel.

In addition to its headquarters and laboratory facility in South San Francisco, California, which it expanded in 2014, the company established the first biochip manufacturing facility in Singapore in 2005.

In 2022, Standard BioTools expanded their offices and manufacturing and research and development facility in Markham, Ontario.[citation needed]

Notes

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Standard BioTools

View on Grokipedia
from Grokipedia
Standard BioTools Inc. is an sciences technology company that develops, manufactures, and commercializes multi-omics instruments, consumables, , and software for biomedical and clinical applications. Formerly known as , the company was founded in 1999 and rebranded to Standard BioTools in following a $250 million strategic capital infusion, with its trading on the under the LAB. In October 2023, Standard BioTools announced an all-stock merger with SomaLogic, Inc., which was completed on January 5, 2024, integrating the latter's platform to enhance its portfolio of standardized next-generation technologies for analyzing proteins, genes, and cells. In June 2025, the company announced the sale of its SomaLogic business to Illumina for up to $425 million, pending regulatory approval and expected to close in 2026. The company's mission is to accelerate breakthroughs in human health by providing high-throughput, reproducible solutions that enable researchers to uncover unique biological insights inaccessible through other methods. Headquartered in , Standard BioTools employs approximately 700 people worldwide (as of November 2025) and serves customers in over 35 countries, with its technologies cited in more than 5,000 peer-reviewed publications. Key offerings include the SomaScan , which measures up to 11,000 proteins from small sample volumes for proteomic profiling; () systems for high-parameter ; and imaging platforms like Hyperion for spatial multi-omics. These tools support applications in , , , and , emphasizing precision and scalability in translational and clinical research. Standard BioTools has received recognition for its innovations, including the "Company to Watch" award in 2019, the technology accolade in 2018, and the Hyperion Imaging System named the No. 1 Innovation in 2017 by The Analytical Scientist. Committed to ethical standards and , the company maintains ISO certifications for its manufacturing and service operations, ensuring reliability for global research programs.

History

Founding and early development

Standard BioTools, originally incorporated as Mycometrix Corporation in May 1999 by , a professor at , and entrepreneur Gajus Worthington, focused on developing microfluidic technologies to enable precise biological analysis at the molecular level. The company's initial efforts centered on commercializing innovations in and integrated fluidic circuits (IFCs), which allowed for the manipulation of small fluid volumes to perform high-throughput assays in and . In April 2001, the company rebranded to Fluidigm Corporation to better reflect its emphasis on fluidic integration for life sciences applications. During its early years, Fluidigm secured multiple venture capital funding rounds to support research and development, raising over $200 million in total pre-IPO investments from investors including Kleiner Perkins Caufield & Byers and Mohr Davidow Ventures. These funds enabled key scientific breakthroughs, such as the development of multilayer soft lithography techniques for creating complex microfluidic devices, which facilitated applications in digital PCR and single-cell analysis. By 2010, Fluidigm held over 110 issued U.S. patents and more than 220 pending applications worldwide, many centered on these innovations, including methods for absolute quantification of nucleic acids via digital PCR and isolation of individual cells for genetic profiling. Fluidigm's first major product launch came in November 2006 with the BioMark system, a real-time PCR platform using IFCs to enable simultaneous analysis of up to 96 samples and 96 targets, revolutionizing and workflows by reducing reagent use and increasing throughput. This system marked the company's entry into commercial markets, targeting academic and pharmaceutical research labs seeking scalable solutions for quantitative genetic analysis. The company's growth culminated in its (IPO) on February 10, 2011, when it raised $75 million by selling 5.6 million shares at $13.50 each on the under the FLDM. This milestone provided capital for expanding manufacturing and product development, solidifying Fluidigm's position in the microfluidics-based life sciences tools sector.

Key acquisitions and expansions

In 2014, Fluidigm Corporation (now Standard BioTools) acquired DVS Sciences, Inc., for approximately $207.5 million in a combination of cash and stock, integrating the mass cytometry system into its portfolio for high-parameter single-cell protein analysis. This acquisition enhanced Fluidigm's capabilities in by adding a complementary technology to its existing platforms, enabling simultaneous analysis of up to 40 protein markers at the single-cell level without antibodies. Earlier, in 2005, Fluidigm established operations in as its hub, opening the region's first facility to support R&D and production of microfluidic technologies. This move expanded the company's global footprint and capacity, leveraging Singapore's economic incentives to scale production of integrated fluidic circuits for genetic . By late 2022, Fluidigm expanded its facility through the transfer of reagent from South , bolstering production capabilities amid strategic operational shifts. This relocation optimized supply chain efficiency and supported growing demand for integrated multi-omics solutions. These developments contributed to revenue growth from $101.9 million in 2017 to $130.6 million in 2021, fueled by expanded offerings in and targeting biopharma and academic sectors. Concurrently, the workforce expanded to 615 employees by December 2021, reflecting investments in talent for R&D and commercial expansion.

Rebranding and recent strategic shifts

In April 2022, Fluidigm Corporation completed a $250 million strategic capital infusion from Casdin Capital and , leading to its as Standard BioTools Inc. to better reflect its focus on providing standardized, high-throughput tools for life sciences , including and applications. The emphasized the company's ambition to deliver essential, scalable solutions for multi-omics analysis, with its common stock beginning to trade on under the ticker "LAB." To bolster its proteomics portfolio, Standard BioTools merged with SomaLogic in an all-stock transaction completed in January 2024, integrating the SomaScan platform, which enables high-plex, aptamer-based protein biomarker discovery and quantification. This acquisition expanded the company's capabilities in data-driven proteomics, allowing for the analysis of thousands of proteins in parallel to support biomarker research and therapeutic development. However, in June 2025, Standard BioTools announced the sale of SomaLogic and related assets to Illumina for up to $425 million, including $350 million in upfront cash and potential milestone payments, to refocus resources on its core mass cytometry and genomics technologies. The transaction, expected to close in the first half of 2026, marked a strategic pivot toward streamlining operations and enhancing efficiency in high-impact areas like imaging mass cytometry. As part of its ongoing transformation, Standard BioTools announced in August 2025 plans to consolidate its South operations into its facility, aiming to co-locate R&D with manufacturing for cost optimization and accelerated innovation. This restructuring, detailed in the company's third-quarter 2025 financial results released on November 4, 2025, is projected to reduce operating expenses while maintaining global R&D momentum. Concurrently, the company reduced its workforce to approximately 539 employees by the end of 2023, with further adjustments—including a 20% cut in the third quarter of 2025 following the SomaLogic sale—to align staffing with its refocused strategy. These shifts underscore Standard BioTools' efforts to enhance operational agility and prioritize sustainable growth in and tools.

Products and technologies

Genomics platforms

Standard BioTools' genomics platforms leverage microfluidic technology to enable high-throughput nucleic acid analysis, focusing on DNA and RNA workflows for research and clinical applications. These systems integrate automated hardware with integrated fluidic circuits (IFCs) to process samples at nanoliter volumes, facilitating scalable assays in gene expression, genotyping, and next-generation sequencing (NGS) library preparation. The Biomark X9 System represents the company's flagship automated platform for real-time PCR, digital PCR, and , utilizing 96.96 Dynamic Array IFCs to support up to 9,216 simultaneous reactions in a single run, generating over 46,000 data points in eight hours. This walk-away system minimizes hands-on time while delivering high-sensitivity results for applications such as and discovery, with and detection optimized for . It also accommodates NGS library preparation workflows, producing PCR data in as little as two hours. Complementing the Biomark X9, the Juno system is a software-controlled automation platform designed specifically for NGS library preparation, integrating target selection, amplification, and enrichment in targeted DNA and RNA sequencing workflows. Capable of processing hundreds of samples daily, Juno employs microfluidic IFCs to streamline library construction for Illumina-compatible sequencers, supporting flexible per-sample throughput from low- to high-volume studies. These platforms find extensive use in via assays like Delta Gene, analysis through absolute quantification software, and sample to enable parallel processing of diverse targets. In research, they aid discovery and validation by profiling hundreds of genes across tens to hundreds of samples, while in infectious disease studies, they support detection and for . The integration of IFCs across both systems enables low-volume, high-sensitivity assays that substantially reduce reagent consumption—often by up to 90% compared to conventional microtiter plate methods—lowering costs without compromising data quality. The evolution of these platforms traces from the earlier BioMark HD system, which introduced high-throughput qPCR and in the , to the current Biomark X9 model launched in , which enhances scalability with increased reaction capacity and automation for clinical and applications. This progression emphasizes broader adoption in , where the X9's benchtop design supports routine high-plex screening in resource-constrained settings.

Proteomics and multi-omics tools

Standard BioTools offers advanced proteomics tools centered on mass cytometry technologies, enabling high-parameter single-cell protein analysis without the limitations of traditional fluorescence-based methods. The Hyperion XTi Imaging System and CyTOF XT mass cytometer are key instruments in this portfolio, utilizing metal-tagged antibodies to profile over 40 cellular parameters simultaneously. The Hyperion XTi system supports imaging mass cytometry (IMC), which provides spatial resolution of protein expression in tissues, while the CyTOF XT facilitates suspension-based cytometry for detailed phenotyping of cell populations. In March 2025, the company launched the CyTOF XT PRO, an enhanced version offering up to 4x faster throughput (2,000 cells per second), improved reproducibility (<9.2% CV), advanced barcoding for >100 samples, and 21 CFR Part 11 compliance for clinical applications. At the core of these tools is technology, a platform that detects rare earth metal isotopes conjugated to antibodies, allowing multiplexed immune cell phenotyping with minimal spectral overlap—a common issue in that can limit parameter depth to around 20 markers. This approach delivers quantitative, high-resolution data on protein abundance and localization, supporting workflows for both tissue imaging via IMC and suspension for dissociated cells. Applications span , where it maps immune cell subsets and activation states; , revealing tumor microenvironments and immune infiltration patterns; and , aiding in target validation and efficacy assessment through multiplexed panels. Following the 2014 acquisition of DVS Sciences by Fluidigm (now Standard BioTools), CyTOF technology was integrated into the company's offerings, leading to significant advancements in system automation and throughput. Post-integration developments include automated sample introduction systems, as seen in the CyTOF XT platform, which streamline high-volume processing and enable up to four times faster acquisition speeds compared to earlier models, enhancing reproducibility for clinical and translational studies. The 2025 CyTOF XT PRO further advances this with regulatory-compliant software and higher parameter support (50+ markers). These improvements have expanded CyTOF's utility in large-scale immune monitoring, with the technology now supporting barcoding for up to 45 samples per run. The tools also facilitate multi-omics integration, combining protein-level insights from and IMC with genomic data to provide a holistic view of cellular function, such as correlating profiles with phenotypic responses in disease models. This potential is realized through complementary workflows where data overlays or single-cell RNA sequencing, offering deeper understanding of mechanisms in and without requiring separate sample preparation.

Consumables and supporting software

Standard BioTools provides a range of , including integrated fluidic circuits (IFCs) and assay kits, that are critical for enabling high-throughput experiments on its microfluidic platforms. These IFCs are pre-filled microfluidic chips designed to automate processes in nanoliter volumes, supporting configurations such as the 96.96 IFC, which allows for up to 9,216 simultaneous PCR reactions across 96 samples and 96 assays. Assay kits typically include the necessary IFCs, preamplification master mixes, reagents, and control line fluids to facilitate applications like analysis in formats such as 24.192, ensuring efficient and reduced reagent consumption compared to traditional methods. For and workflows, the company offers Maxpar antibody panels and metal tags as standardized reagents that enhance reproducibility and enable high-parameter . These panels consist of pre-conjugated antibodies labeled with high-purity metal isotopes, such as (Cd-106 to Cd-116), (Sm-149), and (Pr-141), selected from a library of 51 available tags to minimize spectral overlap and background noise in experiments. The metal tags are conjugated using polymer-based like Maxpar X8 or MCP9, allowing researchers to label monoclonal IgG antibodies for up to 40 reactions per , supporting detailed phenotyping in immuno-oncology and other therapeutic areas. Maxpar OnDemand antibodies provide additional flexibility by offering vetted clones and metal combinations for optimized panel design. Complementing these consumables, Standard BioTools develops supporting software solutions for instrument operation, , and analysis. The Fluidigm Acquisition software, now integrated into the broader software suite (versions such as v9.3), controls instrument functions and facilitates real-time data collection from systems like the XT for applications. For post-acquisition processing, Maxpar Pathsetter software provides automated reporting and visualization tools, capable of identifying and classifying up to 37 distinct immune cell types directly from FCS 3.0 files generated by Maxpar Direct Immune Profiling assays, streamlining workflows from raw data to actionable insights. These digital tools integrate seamlessly with the company's hardware, enhancing data quality and user accessibility without requiring extensive programming expertise. Consumables play a pivotal role in Standard BioTools' recurring , as they are required for ongoing use of installed instruments and drive consistent sales post-purchase. In 2024, consumables accounted for $60.1 million of the company's of $175.1 million, representing approximately 34% of overall sales and underscoring their importance in sustaining long-term . To meet the needs of biopharma clients, Standard BioTools offers customization options for its consumables, including validated panels tailored to specific therapeutic areas such as . Through services like the Maxpar Conjugation Service and modular panel builders, customers can select isotopes, conjugate custom antibodies, and develop bespoke kits for applications in immuno-oncology, with options for up to 42 metal tags and pre-optimized configurations to accelerate research in and clinical translation. These custom solutions ensure compatibility with high-plex assays while maintaining reproducibility across experiments.

Business and operations

Business model and revenue streams

Standard BioTools employs a hybrid business model that combines the sale of specialized instruments as capital equipment with recurring revenue from high-margin consumables and service contracts, fostering customer loyalty and long-term usage in multi-omics research and clinical applications. This structure leverages proprietary technologies in genomics and proteomics platforms, where initial instrument purchases drive ongoing demand for compatible consumables, such as integrated fluidic circuits (IFCs), reagents, and assay kits, as well as services including maintenance, training, and assay performance. The model emphasizes scalability through standardized workflows, particularly post-2022 rebranding and the integration of SomaLogic's proteomics capabilities, to support precision medicine initiatives in biopharmaceutical and translational research. The company sells its products directly through a dedicated sales force targeting academic laboratories, biopharmaceutical firms, and contract research organizations (CROs), with a strategic emphasis on —where the majority of its long-lived assets are located—and regions, including significant operations in . Distributors handle sales in select international territories, such as parts of , the , and , contributing to approximately 59% of total revenue from outside the in 2023. Pricing strategies focus on competitive value and bundling options for instruments and consumables to facilitate integrated multi-omics experiments, though specific figures are negotiated based on customer needs and volume. Historically, as of 2021 under its prior name Fluidigm, revenue was diversified with instruments comprising about 33% ($42.5 million), consumables around 44% ($57.9 million), and the remainder from services and other sources, reflecting a shift toward recurring streams over time. This mix has continued to evolve, with consumables and services forming the core of high-margin revenue in recent years—for instance, in , consumables reached $60.1 million and instruments $28.5 million from continuing operations—further influenced by the announced 2025 sale of the SomaLogic business to Illumina for up to $425 million, expected to close in the first half of 2026.

Global facilities and manufacturing

Standard BioTools maintains its and primary (R&D) hub at 2 Tower Place, Suite 2000, 94080, where administrative functions and core innovation activities are centralized. This 78,000-square-foot facility, leased since March 2020, supports the company's and platforms through dedicated laboratory space, though approximately 50% of the premises have been subleased as part of ongoing operational optimizations. In August 2025, the company announced plans to consolidate its South San Francisco R&D operations into its facility to co-locate research with manufacturing, aiming to enhance efficiency; this restructuring is expected to incur approximately $3.6 million in costs and impact U.S.-based employees. In September 2025, this restructuring plan was expanded to include a global reduction-in-force of approximately 20% of the workforce. The company's operations are distributed across key global sites to ensure scalable production of instruments, , and . In , Standard BioTools operates a 40,000-square-foot facility at Techplace II, Block 5008, #08-08, Avenue 5, established in 2005 as the first site in the and expanded to include advanced clean rooms for producing integrated fluidic circuits (IFCs) and assembling microfluidics-based analytical instruments. This :2016-certified site serves the market with high-volume output of tools, including real-time PCR and NGS library preparation components, and features insourced assembly processes initiated in 2022 to bolster . In , , the company runs specialized manufacturing and R&D at 1380 Rodick Road, Suite 400, encompassing approximately 72,500 square feet across multiple leased spaces. This facility, acquired through the 2014 purchase of DVS Sciences for $207.5 million, focuses on antibody conjugation, reagents, instruments, and assays, with production transferred from South San Francisco in late 2022 to centralize expertise. Certified to :2016 standards, it adheres to good manufacturing practices (GMP) for reagent production, supporting high-parameter single-cell protein analysis tools. Additional manufacturing occurs at a CLIA-certified and CAP-accredited laboratory in , at 2945 Wilderness Place, spanning 60,000 square feet and dedicated to and SomaScan kits for applications, which is included in the pending sale of the SomaLogic business to Illumina announced in June 2025 and expected to close in the first half of 2026. Standard BioTools' depends on sole or limited-source third-party suppliers for specialized components such as metals and elements, without long-term contracts, while achieving through in-house production of key and consumables at its and Canadian sites to mitigate risks and maintain under GMP guidelines. As of December 31, 2023, prior to the SomaLogic merger closing in January 2024, the company employed 539 individuals worldwide, including approximately 130 in the United States and 409 in non-U.S. locations. Post-merger, headcount rose to approximately 928 employees, with 510 in the U.S. and 418 internationally. In September 2025, the company announced a global workforce reduction of approximately 20% as part of its plan.

Financial performance and market position

Standard BioTools experienced fluctuating revenue in the early 2020s, with total revenue reaching $130.6 million in 2021 before declining to $98.0 million in 2022 amid broader market challenges in the biotechnology sector. The company saw a modest rebound to $106.3 million in 2023, driven by core product sales, though this figure excluded the full-year impact of its merger with SomaLogic, which closed in January 2024 and boosted 2024 revenue to $174.4 million. In June 2025, Standard BioTools announced the sale of its SomaLogic proteomics business to Illumina for up to $425 million, expected to close in the first half of 2026 and anticipated to streamline operations toward core genomics platforms while adding to cash reserves upon completion. For the third quarter of 2025, total combined revenue was $46.2 million, with continuing operations at $19.6 million. The company ended 2024 with approximately $293 million in cash, cash equivalents, and short-term investments. The company's shares trade on Nasdaq under the ticker LAB, with a market capitalization of approximately $448 million as of November 2025, down from a post-2022 investment valuation near $300 million amid ongoing biotech sector volatility. Stock performance has been pressured by macroeconomic factors, including funding constraints in life sciences research, resulting in a share price around $1.18 by mid-November 2025. Net losses have persisted but shown variability; the company reported a $59.2 million net loss in 2021, escalating to $190.1 million in 2022 due to impairment charges, before narrowing to $74.7 million in 2023 and widening again to $138.9 million in 2024 amid integration costs from the SomaLogic merger. Standard BioTools maintains a leadership position in technology, a niche within single-cell where it pioneered high-parameter analysis as the original developer of the platform, outpacing traditional providers like BD Biosciences in capabilities. However, it faces intensifying competition from emerging spatial tools offered by companies such as and NanoString Technologies, which integrate transcriptomics and in tissue contexts. investments have consistently represented 25-35% of annual revenue, with $38 million spent in 2021 (29% of revenue) rising to $62 million in 2024 (36% of revenue), emphasizing enhancements and next-generation platforms to sustain innovation amid competitive pressures.

Leadership and governance

Executive leadership

Michael Egholm, Ph.D., has served as President and of Standard BioTools since April 2022, leading the company's strategic initiatives including the 2022 rebranding from Fluidigm and a $250 million capital infusion from Casdin Capital and to support growth in multi-omics technologies. With over 25 years of experience in and life sciences, Egholm previously held roles as at Danaher Life Sciences and at Roche's 454 Life Sciences, where he contributed to advancements in sequencing and holds 40 U.S. patents in biopharma . Under his leadership, Standard BioTools completed the merger with SomaLogic in January 2024, integrating capabilities to expand its multi-omics portfolio, and navigated a challenging biotech market by stabilizing operations and achieving merger synergies with a run-rate of $90 million by the end of 2024. In June 2025, Egholm oversaw the announcement of the strategic sale of its SomaLogic subsidiary to Illumina for up to $425 million, expected to close in the first half of 2026, positioning the company for focused growth in its core and tools amid ongoing industry consolidation. Hanjoon Alex Kim serves as and Principal Officer, having assumed the role on an interim basis in August 2024 following the departure of Jeff Black and becoming permanent thereafter, with a focus on post-merger financial consolidation and operational efficiencies. Kim, a co-founder of Standard BioTools, brings over 20 years of experience in healthcare finance, including as President of Milliken’s Healthcare Division, where he managed more than 40 transactions; he holds BS and MS degrees in and an MBA from . His contributions include driving revenue growth and IT/legal oversight during the SomaLogic integration and the announced 2025 asset sale. Stephen A. Williams, MD, Ph.D., acts as , leading since the 2024 SomaLogic merger, with expertise in clinical applications of the SomaScan platform. Williams, who joined SomaLogic in 2009, has 18 years of prior experience at in clinical R&D and holds an MD and PhD from , contributing to high-impact advancements in precision medicine commercialization. The executive team demonstrates deep expertise, with multiple members holding PhDs or MDs in , chemistry, or related fields, and an average of over 20 years in life sciences and tools development. There has been no major executive turnover since the announcement of the 2025 SomaLogic sale, underscoring a commitment to leadership continuity amid strategic shifts.

Board of directors and corporate structure

Standard BioTools Inc. maintains a board of seven directors as of 2025, with six independent members comprising the majority to align with best practices in . The board is structured in three staggered classes—Class I (three directors), Class II (two directors), and Class III (two directors)—to ensure continuity and stability in oversight. Thomas D. Carey serves as the independent Chairman, bringing expertise from his role as founder and former Managing Director of Perspective Group, a life sciences investment firm. This leadership structure, with an independent chair separate from the CEO, supports robust board oversight of management while complying with Global Select Market listing standards. Key directors include biotech veterans and financial experts who contribute specialized knowledge to strategic decision-making. Michael Egholm, Ph.D., the President and CEO, serves as the sole non-independent director, leveraging his extensive experience in life sciences leadership. Independent members feature Frank R. Witney, Ph.D., an at Ampersand Capital Partners and former CEO of , providing deep industry insights; Troy Cox, former CEO of Foundation Medicine, with expertise in and diagnostics; and Kathy Hibbs, former Chief Administrative Officer at , offering perspectives on clinical and regulatory matters in . Financial acumen is represented by Eli Casdin, Founder and of Casdin Capital, LLC, a firm focused on biotech s; Fenel M. , Managing Partner at P&M Capital Partners, LLC; and Chairman Carey. These directors' backgrounds in , , and operations enable the board to guide the company's innovation in and tools. The board operates through three standing committees to fulfill its duties and ensure . The , chaired by Fenel M. Eloi and comprising Troy Cox, Kathy Hibbs, and Frank Witney—all independent and financially literate—oversees financial reporting, internal controls, and external audits in accordance with SEC requirements. The Human Capital Committee, formerly the Compensation Committee and chaired by Frank Witney with members Eli Casdin and Troy Cox, manages , equity incentives, and talent strategies, adhering to independence rules. The Nominating and Committee, led by Chairman Thomas Carey and including Eli Casdin and Kathy Hibbs, handles director nominations, board evaluations, and governance policies, promoting diversity and ethical standards. In 2024, these committees held a total of 20 meetings, reflecting active engagement. As a Delaware-incorporated , Standard BioTools operates under a traditional structure that facilitates governance and investor protections. The company maintains wholly owned subsidiaries, including Standard BioTools Canada Inc. in , for North American operations, and Standard BioTools Singapore Pte. Ltd. in , supporting activities and manufacturing. This international footprint enables efficient global expansion while centralizing strategic control at the parent level. Governance practices have evolved to emphasize and accountability, with an enhanced focus on environmental, social, and governance (ESG) principles following the April 2023 ESG Report. This includes commitments to , , and UN Global Compact standards, integrated into processes to mitigate risks and support long-term value creation. In October 2023, the board adopted a policy for in line with SEC and mandates, further strengthening ethical oversight. The company upholds a Code of Business Conduct and , available publicly, with no reported major controversies affecting board .

References

  1. https://www.standardbiotools.com/about/our-story
  2. https://investors.standardbio.com/news-releases/news-release-details/fluidigm-completes-250-million-strategic-capital-infusion-and
  3. https://investors.standardbio.com/news-releases/news-release-details/standard-biotools-and-somalogic-combine-all-stock-merger
  4. https://investors.standardbio.com/news-releases/news-release-details/standard-biotools-completes-merger-somalogic-creating
  5. https://investors.standardbio.com/news-releases/news-release-details/standard-biotools-enters-next-phase-transformation-strategic
  6. https://www.genomeweb.com/business-news/standard-biotools-cut-workforce-20-percent-q3-revenues-fall-11-percent
  7. https://www.standardbiotools.com/products-services/technologies
  8. https://www.standardbiotools.com/footer-nav/resources/iso-certification
  9. https://www.sec.gov/Archives/edgar/data/1162194/000119312510273807/ds1.htm
  10. https://globalventuring.com/blog/2011/02/13/fluidigm-floats-at-range-bottom/
  11. https://www.biospace.com/fluidigm-corporation-launches-biomark-system-to-shake-up-billion-dollar-market-for-real-time-qpcr-assays
  12. https://www.renaissancecapital.com/IPO-Center/News/8974/Fluidigm-sets-terms-for-%2475-million-IPO
  13. https://investors.standardbio.com/news-releases/news-release-details/fluidigm-completes-acquisition-dvs-science
  14. https://www.annualreports.com/HostedData/AnnualReportArchive/f/NASDAQ_FLDM_2010.pdf
  15. https://www.sec.gov/Archives/edgar/data/1162194/000116219423000013/fldm-20221231.htm
  16. https://investors.standardbio.com/news-releases/news-release-details/fluidigm-announces-fourth-quarter-and-full-year-2017-financial
  17. https://investors.standardbio.com/news-releases/news-release-details/fluidigm-announces-preliminary-revenue-exceeding-guidance-fourth
  18. https://www.annualreports.com/HostedData/AnnualReportArchive/s/NASDAQ_LAB_2021.pdf
  19. https://www.globenewswire.com/news-release/2022/04/04/2416137/0/en/Fluidigm-Completes-250-Million-Strategic-Capital-Infusion-and-Changes-Name-to-Standard-BioTools-Inc.html
  20. https://www.globenewswire.com/news-release/2025/06/23/3103269/0/en/Standard-BioTools-Enters-Next-Phase-of-Transformation-with-Strategic-Sale-of-SomaLogic-to-Illumina.html
  21. https://investors.standardbio.com/news-releases/news-release-details/standard-biotools-reports-third-quarter-2025-financial-results
  22. https://www.globenewswire.com/news-release/2025/11/04/3180850/0/en/Standard-BioTools-Reports-Third-Quarter-2025-Financial-Results.html
  23. https://investors.standardbio.com/static-files/7e7ad0d4-3c44-4693-adc8-01adb098f74b
  24. https://www.standardbiotools.com/products/technologies/microfluidics
  25. https://www.standardbiotools.com/biomark-x9
  26. https://www.standardbiotools.com/x9
  27. https://www.standardbiotools.com/area-of-interest/genomics-analysis/ngs-library-prep
  28. https://www.standardbiotools.com/area-of-interest/genomics-analysis/ngs-library-prep/targeted-sequencing/targeted-sequencing-with-microfluidics
  29. https://www.standardbiotools.com/area-of-interest/genomics-analysis/pcr-applications
  30. https://www.standardbiotools.com/genomics-clinical-and-translational-research
  31. https://www.standardbiotools.com/TechnicalDocuments/Lookbooks/GenomicAnalysisEBook.pdf
  32. https://www.youtube.com/watch?v=Bse5wneEwoM
  33. https://www.standardbiotools.com/products-services/instruments/hyperion-plus
  34. https://www.standardbiotools.com/helios-instrument
  35. https://www.standardbiotools.com/products-services/technologies/imaging-mass-cytometry
  36. https://www.standardbiotools.com/area-of-interest/dual-mode
  37. https://www.standardbiotools.com/resources/news-center/cytof-xt-pro-system-launches-with-innovations-for-clinical-trial-research_article
  38. https://www.standardbiotools.com/products-services/instruments/cytof-xt
  39. https://www.standardbiotools.com/area-of-interest/biomarker-discovery/biomarker-discovery-with-imaging-mass-cytometry
  40. https://www.standardbiotools.com/cytof-xt-pro
  41. https://www.standardbiotools.com/products/kits-reagents-and-accessories/genomics/integrated-fluid-circuits-ifcs
  42. https://www.standardbiotools.com/products/kits-reagents-and-accessories/custom-reagents
  43. https://www.standardbiotools.com/MOD
  44. https://www.standardbiotools.com/products/software/maxpar-pathsetter
  45. https://www.standardbiotools.com/products/software/cytof-software-v9
  46. https://investors.standardbio.com/news-releases/news-release-details/standard-biotools-reports-fourth-quarter-and-full-year-2024
  47. https://www.standardbiotools.com/resources/panel-design
  48. https://www.sec.gov/Archives/edgar/data/1162194/000095017024023845/lab-20231231.htm
  49. https://www.sec.gov/Archives/edgar/data/1162194/000116219422000021/fldm-20211231.htm
  50. https://investors.standardbio.com/news-releases/news-release-details/standard-biotools-enters-next-phase-transformation-strategic-sale-somalogic-illumina
  51. https://www.sec.gov/Archives/edgar/data/1162194/000095017025112662/lab-20250828.htm
  52. https://www.bionity.com/en/news/49725/fluidigm-opens-singapore-s-first-biochip-fab.html
  53. https://www.standardbio.com/iso
  54. https://investors.standardbio.com/news-releases/news-release-details/fluidigm-acquire-dvs-sciences
  55. https://finance.yahoo.com/quote/LAB/financials/
  56. https://www.wsj.com/market-data/quotes/LAB/financials/annual/balance-sheet
  57. https://www.nasdaq.com/market-activity/stocks/lab
  58. https://finance.yahoo.com/quote/LAB/history/
  59. https://www.standardbio.com/resources/learning-centers/what-is-mass-cytometry
  60. https://seekingalpha.com/article/4792048-standard-biotools-too-early-to-determine-fate-of-turnaround
  61. https://www.macrotrends.net/stocks/charts/LAB/standard-biotools/research-development-expenses
  62. https://www.bloomberg.com/profile/person/16762447
  63. https://www.standardbio.com/about/management
  64. https://www.illumina.com/company/news-center/press-releases/press-release-details.html?newsid=3214bfaf-0c8c-4c58-9784-a446caca285b
  65. https://www.globenewswire.com/news-release/2024/07/31/2922212/0/en/Standard-BioTools-Announces-Senior-Leadership-Changes.html
  66. https://www.morningstar.com/stocks/xnas/lab/executive
  67. https://people.equilar.com/bio/person/michael-egholm-standard-biotools-inc/34966444
  68. https://investors.standardbio.com/static-files/fc3ee769-25ff-4595-bb12-a7693afccd12
  69. https://investors.standardbio.com/corporate-governance/board-of-directors
  70. https://investors.standardbio.com/corporate-governance/committeecomposition
  71. https://www.sec.gov/Archives/edgar/data/1162194/000095017024023845/lab-ex21_1.htm
  72. https://investors.standardbio.com/corporate-governance/governance-overview
Add your contribution
Related Hubs
User Avatar
No comments yet.